TMCnet - World's Largest Communications and Technology Community



Research and Markets: Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
[February 13, 2014]

Research and Markets: Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering.

'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM).

Key Topics Covered:


Recurrent Glioblastoma Multiforme (GBM) Overview

Therapeutics Development

Clinical Stage Products

Early Stage Products

Drug Profiles

bosutinib - Drug Profile

axitinib - Drug Profile

onartuzumab - Drug Profile

dacomitinib - Drug Profile

rindopepimut - Drug Profile

VB-111 - Drug Profile

ANG-1005 - Drug Profile

AT-101 - Drug Profile

vorinostat - Drug Profile

buparlisib hydrochloride - Drug Profile

pazopanib hydrochloride - Drug Profile

memantine hydrochloride - Drug Profile

galunisertib - Drug Profile

G-200 - Drug Profile

ERC-1671 - Drug Profile

lenvatinib - Drug Profile

trebananib - Drug Profile

TB-403 - Drug Profile

nabiximols - Drug Profile

golvatinib - Drug Profile

ARC-100 - Drug Profile

New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile

vocimagene amiretrorepvec + flucytosine ER - Drug Profile

golvatinib + lenvatinib - Drug Profile

ICT-121 - Drug Profile

BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile

AZD-7451 - Drug Profile

DNX-2401 - Drug Profile

OS-2966 - Drug Profile

Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates

Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects

Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones

Featured News & Press Releases


Companies Mentioned

F. Hoffmann-La Roche Ltd.

Amgen Inc.

AstraZeneca PLC

Eli Lilly and Company

GlaxoSmithKline plc

Agenus, Inc.

Merck & Co., Inc.

Novartis AG

Eisai Co., Ltd.

Pfizer Inc.

GW Pharmaceuticals plc

Celldex Therapeutics, Inc.

ImmunoCellular Therapeutics, Ltd.

ThromboGenics NV

AngioChem Inc.

Ascenta Therapeutics, Inc.

Vascular Biogenics Ltd.

Archer Biosciences, Inc

Tocagen Inc.

DNAtrix, Inc.

ERC Belgium SA

OncoSynergy Inc

For more information visit

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy